Phaseline

Targets › IL23A

IL23A (Interleukin-23 subunit alpha): drug programs, companies and trials

13 programs from 11 companies in 162 trials: 49 Phase 2, 46 Phase 3, 45 Phase 4, 22 Phase 1; Immunology, Other, Gastroenterology; next expected readout Dec 2026.

Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity. Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4. (UniProt, Q9NPF7)

Open in Phaseline: the race on IL23A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
University of CalgaryCBD 100 mg OD
Interleukin-23 inhibitor
CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1Phase 4Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope …Dec 2026
Johnson & Johnson (Janssen)Guselkumab (CNTO1959)
Interleukin-23 inhibitor
IL12B, IL23APhase 4Arthritis, Psoriatic; Psoriasis; Colitis, Ulcerative; Crohn's Disease …Dec 2026
Eli LillyMirikizumab (LY3074828)
Interleukin-23 inhibitor
IL12B, IL23APhase 4Lactation; Crohn's Disease; Ulcerative Colitis; Colitis, Ulcerative …Feb 2027
Psoriasis Treatment Center of Central New JerseyIlumya
IL-23 inhibitor
IL23APhase 4Psoriasis–
Sixth Affiliated Hospital, Sun Yat-sen UniversityInterleukin-23 monoclonal antibody
IL-23 inhibitor; anti-IL-23 monoclonal antibody
IL23APhase 4Crohn's Disease and Ulcerative Colitis–
AbbVieRisankizumab
Interleukin-23 inhibitor
IL12B, IL23APhase 3Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Crohn's Disease (CD) …Jan 2027
Sun Pharmaceutical IndustriesTildrakizumab
Interleukin-23 inhibitor
IL12B, IL23APhase 3Active Psoriatic Arthritis; Moderate to Severe Genital Psoriasis; Psoriatic Arthritis; Moderate-to-severe Chronic Plaque PsoriasisFeb 2027
Johnson & Johnson (Janssen)Ustekinumab
Interleukin-12 inhibitor; Interleukin-23 inhibitor
IL12B, IL12A, IL23APhase 3Crohn Disease; Psoriasis; Crohn Disease (CD); Type 1 Diabetes Mellitus …Sep 2027
Qilu PharmaceuticalQL2106 injection
IL-23 inhibitor
IL23APhase 3Plaque PsoriasisDec 2027
Johnson & Johnson (Janssen)JNJ-78934804
IL-23 inhibitor
IL23APhase 3Crohn Disease; Colitis, Ulcerative; Crohn's DiseaseJun 2028
Innovent Biopharmaceutical Technology (Hangzhou)IBI112
IL-23 inhibitor
IL23APhase 3PsoriasisJan 2029
Chong Kun Dang PharmaceuticalCKD-704
Risankizumab biosimilar; anti-IL-23 monoclonal antibody
IL23APhase 1Psoriasis–

Conditions

Crohn's Disease (12) Psoriasis (11) Crohn Disease (10) Ulcerative Colitis (9) Colitis, Ulcerative (5) Psoriatic Arthritis (4) Crohn Disease (CD) (3) Psoriasis Vulgaris (3) Nicotine Dependence (3) Ulcerative Colitis (UC) (2) Pouchitis (2) Arthritis, Psoriatic (2)

Modalities

antibody (5), small molecule (5), protein or peptide (2), mixed (1)

Companies

Johnson & Johnson (Janssen) (3) AbbVie (1) Eli Lilly (1) Sun Pharmaceutical Industries (1) Sixth Affiliated Hospital, Sun Yat-sen University (1) University of California, San Francisco (1) University of Calgary (1) Chong Kun Dang Pharmaceutical (1) Innovent Biopharmaceutical Technology (Hangzhou) (1) Psoriasis Treatment Center of Central New Jersey (1) Qilu Pharmaceutical (1)

Related targets

IL12B (7) ADRB2 (2) NR3C1 (2) HTR2A (2) AGTR1 (1) PDCD1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1) CHRM3 (1) CHRM2 (1) ADRB3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.